AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8977984
Drug: 1M depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1M depot formulation
Trial: 8977984
Drug: 3M depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3M depot formulation
Trial: 1608405
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Heparin and Aspirin)
Trial: 1608405
Drug: Neither treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither treatment (placebo)
Trial: 26361994
Drug: Venlafaxine (18.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (18.75 mg/day)
Trial: 19809363
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg once daily for 4 weeks, then randomized to valsartan 160, 320, or 640 mg/day for 26 weeks
Trial: 19809363
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 or 640 mg/day
Trial: 16197283
Drug: Fast ForWord
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast ForWord (FFW) intervention, home-based therapy for 6 weeks
Trial: 11834877
Drug: Dilazep dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep dihydrochloride (300 mg/day, n = 20)
Trial: 7258754
Drug: Bretylium tosylate
RxNorm normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bretylium tosylate (10 mg/kg)
Trial: 26786042
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg three times daily for 3 days)
Trial: 21136333
Drug: 5-day glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day glucocorticoid treatment followed by 9 days of placebo
Trial: 21136333
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of systemic glucocorticoids (40 mg of prednisone-equivalent daily)
Trial: 14706762
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein containing 99 mg naturally occurring isoflavones
Trial: 11871584
Drug: Assured Treatment
RxNorm normalized name: Assured Pain Relief KIT
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assured Treatment (AT)
Trial: 11871584
Drug: Disbeliever Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disbeliever Treatment (DT)
Trial: 11871584
Drug: Non-Targeted Treatment
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Targeted Treatment (NT)
Trial: 9926278
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 2‐8 mg/day orally for 8‐12 weeks
Trial: 7819982
Drug: DICE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DICE therapy
Trial: 7819982
Drug: Red dice
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red dice therapy
Trial: 28070889
Drug: Guided parent-delivered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided parent-delivered cognitive behaviour therapy (CBT)
Trial: 26047719
Drug: Parent presence
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent presence during speech preparation (N=39)
Trial: 26047719
Drug: Stranger presence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stranger presence during speech preparation
Trial: 26047719
Drug: Parent presence
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent presence during speech preparation
Trial: 23115341
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change condition (yellow tablet 'Betaprol')
Trial: 23115341
Drug: Generic change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic change condition (white tablet 'Generic')
Trial: 23115341
Drug: Branded change
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded change condition (white tablet 'Novaprol')
Trial: 540525
Drug: Piracetam (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (2.4 g per day)
Trial: 31125823
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 20 mg tid for 14 days
Trial: 20073212
Drug: Compound salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound salvia injection (20 mL in 10% glucose 500 mL for intravenous dripping once a day) and UDCA (15 mg, thrice daily by oral taken)
Trial: 17526181
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (Control group II)
Trial: 2591060
Drug: Octreotide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (250 micrograms/day in 4 divided s.c. injections for 1 month, followed by continuous s.c. infusions for another month, then 200 micrograms three times daily as s.c. injections)
Trial: 22379151
Drug: Octreotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide treatment
Trial: 31833226
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (1 day and 4 days)
Trial: 31833226
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (4 days)
Trial: 28291237
Drug: 4-L split-dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-L split-dose polyethylene-glycol (PEG) regimen
Trial: 28291237
Drug: 2-L split-dose
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L split-dose PEG plus ascorbic acid (PEG+Asc) regimen
Trial: 21866432
Drug: Hydrocortisone 1
RxNorm normalized name: hydrocortisone 1 MG
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 1 mg·kg(‐1) iv
Trial: 21866432
Drug: Hydrocortisone 2
RxNorm normalized name: hydrocortisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 2 mg·kg(‐1) iv
Trial: 11777191
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate liquid suspension 800 mg/day
Trial: 11777191
Drug: Dronabinol tablets
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol tablets 2.5 mg b.i.d.
Trial: 11777191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of megestrol acetate and dronabinol
Trial: 8027215
Drug: Octreotide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (4 months treatment)
Trial: 2917597
Drug: Viqualine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viqualine 75 mg bd
Trial: 2917597
Drug: Ethanol (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (blood alcohol concentrations of 17-22 mmol.l-1)
Trial: 4149613
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and other beta-blockers
Trial: 28057361
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Trial: 28057361
Drug: adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23)
Trial: 11403980
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA daily for 13 weeks
Trial: 9409946
Drug: Quinolones (ciprofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinolones (ciprofloxacin, 500 mg/12 h per os; pefloxacin, 200 mg/12 h intravenous)
Trial: 9409946
Drug: Tetracyclines (rolitetracycline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracyclines (rolitetracycline, 275 mg/12 h intravenous)
Trial: 8323891
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (1.0 mcg.kg‐1h‐1)
Trial: 8323891
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (0.5 mcg.kg‐1 x h‐1) and clonidine (0.3 mcg.kg‐1 x h‐1)
Trial: 3095503
Drug: Triple-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug combination of methotrexate (MTX), 5-fluorouracil (5-FU), and cisplatin
Trial: 29298124
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 μg twice/day
Trial: 29298124
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 μg twice/day
Trial: 27664217
Drug: Immediate insertion
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate insertion of etonogestrel releasing implant (inserted 1 hour after mifepristone intake)
Trial: 27664217
Drug: Routine insertion
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine insertion of etonogestrel releasing implant (inserted at follow-up 2-4 weeks later)
Trial: 27664217
Drug: Immediate insertion
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate insertion of etonogestrel releasing implant
Trial: 27664217
Drug: Routine insertion
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine insertion of etonogestrel releasing implant
Trial: 22935338
Drug: Quercetin (Q)
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (Q) 1095 mg
Trial: 19011774
Drug: 1.2 ml
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine with 0.16 mg of morphine (group BM)
Trial: 19011774
Drug: 1.2 ml
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine (group B)
Trial: 10984265
Drug: subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous octreotide
Trial: 3099490
Drug: Transdermally applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermally applied nitroglycerin (TDS) 5.0 mg in 24 hours
Trial: 3099490
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release nitroglycerin capsules (NTR) 2.5 mg
Trial: 29301785
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid therapy (LDL-C <70 mg/dL)
Trial: 24593225
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) 100 cc, 0.7 mM polyphenols, three times a week for one year
Trial: 18925346
Drug: Specialized behavioral
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized behavioral therapy + placebo + medical management
Trial: 18925346
Drug: Specialized behavioral
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized behavioral therapy alone
Trial: 12638641
Drug: 5-HT-selective pharmacotherapy
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT-selective pharmacotherapy
Trial: 9827783
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin sodium with a 5‐day hospitalization
Trial: 9827783
Drug: Ardeparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ardeparin and Unfractionated heparin
Trial: 29209778
Drug: Prourokinase injection
RxNorm normalized name: urokinase Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prourokinase injection (20 mg intravenously followed by 30 mg intravenous infusion within 30 min)
Trial: 29209778
Drug: Prourokinase injection
RxNorm normalized name: urokinase Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prourokinase injection
Trial: 25129820
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no intravenous metoprolol)
Trial: 9154893
Drug: Inhaled leukotriene
RxNorm normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled leukotriene B4 (17.6 +/- 3.4 microg for normal subjects; 18.2 +/- 1.9 microg for asthmatics)
Trial: 4074450
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg proglumetacin t.i.d.
Trial: 4074450
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indometacin t.i.d.
Trial: 24635880
Drug: 3-monthly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly monitoring
Trial: 24635880
Drug: 6-monthly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly monitoring
Trial: 24635880
Drug: Cost-effectiveness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness of 6-monthly monitoring
Trial: 22128444
Drug: Epidural steroid/local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid/local anesthetic injection (Group 2)
Trial: 17927726
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route (Group 1): ketamine (6 mg/kg), midazolam (0.05 mg/kg), atropine (0.02 mg/kg)
Trial: 17927726
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route (Group 2): ketamine (10 mg/kg), midazolam (0.2 mg/kg), atropine (0.05 mg/kg)
Trial: 15105231
Drug: Morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 100 microg
Trial: 15321310
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 microg and Morphine 100 microg
Trial: 2027118
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug
Trial: 31599468
Drug: Sequential Multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Multiple Assignment Randomized Trial (SMART) design
Trial: 23509932
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care group (standard early oral health screening program; 'lift the lip')
Trial: 21786489
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of normal saline
Trial: 19078947
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel alpha2delta ligands (lead compound at approximately 30 mg)
Trial: 19078947
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel alpha2delta ligands (backup compound at >600 mg)
Trial: 16877536
Drug: Cluster of
RxNorm normalized name: Cluster of differentiation 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster of three IRS-related conditions (hypertension, BMI >/=25 kg/m(2), HDL cholesterol <40 mg/dl)
Trial: 17609247
Drug: Mifepristone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (5 mg daily)
Trial: 17609247
Drug: Levonorgestrel (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (0.03 mg progestogen-only pill)
Trial: 17609247
Drug: Mifepristone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (5 mg daily) with condoms
Trial: 16216596
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet rich in fruits, vegetables and low-fat dairy products, reduced in fat (27%), saturated fat (7%), and cholesterol (150 mg/day) for 3 months
Trial: 12220692
Drug: Polish patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polish patients on aspirin before stroke
Trial: 8120559
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron plus dexamethasone
Trial: 8120559
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron alone
Trial: 31290715
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugated vaccine (PCV13)
Trial: 30215583
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Trial: 31290715
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (PPV23 and PCV13)
Trial: 24385202
Drug: Anti-TNFα therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα therapy (infliximab and etanercept)
Trial: 21469401
Drug: Chemomechanical (papain‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemomechanical (papain‐based gel followed by curette)
Trial: 3138446
Drug: OpSite dressings
RxNorm normalized name: DRESSING,OPSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OpSite dressings changed twice weekly (OpS-ICU)
Trial: 19602839
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (isoleucine:leucine:valine=1:2.3:1.2) at 0.1 g/kg body weight 15 min before squat exercise
Trial: 19602839
Drug: Placebo (dextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrin) at 0.1 g/kg body weight 15 min before squat exercise
Trial: 14678375
Drug: Intravesical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical prostaglandin E2 (1.5 mg in 20 mL 0.9% saline) plus oral bethanechol chloride (50 mg four times daily) for 6 weeks
Trial: 14678375
Drug: Saline instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline instillation plus placebo tablets for 6 weeks
Trial: 10210973
Drug: Two nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two nucleoside analogues and one protease inhibitor
Trial: 7596211
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment teams with extensive training in in vivo treatment
Trial: 7596211
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management program emphasizing office-based treatment
Trial: 656357
Drug: Pilocarpine in
RxNorm normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine in an oily solution
Trial: 656357
Drug: Pilocarpine in
RxNorm normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine in aqueous solution
Trial: 6797663
Drug: Alternative drugs
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative drugs (specific drugs not mentioned)
Trial: 6797663
Drug: Treatment-free interval
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free interval between drugs
Trial: 6797663
Drug: Gold, penicillamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold, penicillamine, levamisole (as first second-line drug)
Trial: 25701002
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg DHA
Trial: 19568197
Drug: L‐arginine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐arginine hydrochloride capsules (7.2 g x d(‐1))
Trial: 10409565
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g/kg/day for 5 days)